Publications by authors named "Ingrid Helsen"
Autologous hematopoietic stem cell transplantation (autoHSCT) is a standard of care for patients with hemato-oncologic diseases. This procedure is highly regulated, and a quality assurance system needs to be in place. Deviations from defined processes and outcomes are reported as adverse events (AEs: any untoward medical occurrence temporally associated with an intervention that may or may not have a causal relationship), including adverse reactions (ARs: a response to a medicinal product which is noxious and unintended).
View Article and Find Full Text PDFArticle Synopsis
- Increased cell proliferation in acute lymphoblastic leukemia (ALL) is linked to genetic changes affecting prognosis, with telomere length (TL) and telomerase activity (TA) being key factors in assessing patient risk.
- In patients with ALL, lymphoblasts showed significantly shorter TL compared to normal B- and T-lymphocytes, and high-risk pediatric patients exhibited higher TA, indicating a potential correlation between TA and disease severity.
- The use of the telomerase inhibitor imetelstat demonstrated that it can effectively induce apoptosis in B-ALL cells in vitro, suggesting that targeting telomerase may enhance current treatments for ALL by helping to identify and treat high-risk patients.